I-Mab IMAB · Stock Open I-Mab in new tab
Analyst price targets
Recent rating changes, newest first
I-Mab Analysis (IMAB)
Is I-Mab a good investment? I-Mab (IMAB) is currently trading at 2.88 USD. Market analysts have a consensus price target of 8.60 USD. This suggests a potential upside from current levels.
Earnings Schedule: I-Mab is expected to release its next earnings report on April 1, 2026. The market consensus estimate for Forward EPS is -1.47.
Investor FAQ
Does I-Mab pay a dividend?
No, it does not currently pay a dividend.
What asset class is I-Mab?
I-Mab is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be April 1, 2026. The company currently has a trailing EPS of -0.51.
Company Profile
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Community Discussion